Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.

During the last 4 weeks of the DB period, LSM (SE) decreases from baseline in PHQ‐9 scores were greater in the quarterly and monthly fremanezumab groups (−1.3 [0.4] and −1.8 [0.3], respectively) compared with the placebo group (−0.7 [0.3]; p = 0.082 and p = 0.004, respectively; Figure 6A ), although the difference between quarterly fremanezumab and placebo did not reach statistical significance. 16 At 6 months, patients receiving fremanezumab reported improvement in PHQ‐9 scores (mean [SD] and percentage decrease from baseline: DB quarterly fremanezumab, −2.4 [5.3] and 55.8%; DB monthly fremanezumab, −1.6 [5.5] and 45.7%; DB placebo, −2.0 [4.9] and 51.3%; Figure 6B ).

also in 111,027 other papers